Biogen announces new data providing further evidence for SPINRAZA (nusinersen) as a treatment for SMA - Spinal News International
EMA opinion on broad-label approval for Spinraza – TreatSMA
What is Spinraza? Uses, Side Effects & More | TheSocialMedwork
A potential side effect added to Spinraza label – TreatSMA
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
Study design | SPINRAZA® (nusinersen) HCP
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
Biogen provides information on upcoming Spinraza EU label | SMA Europe
From Idea to Injection: How Spinraza Came to Be - SMA News Today
HSE to consider funding Spinraza as NHS approves muscle-wasting therapy
Farmalisa - Spinraza is a medicine used to treat 5q spinal muscular atrophy (SMA), a genetic disease that causes weakness and wasting of the muscles including the lung muscles. The disease is
5. Spinraza | FiercePharma
These highlights do not include all the information needed to use SPINRAZA® safely and effectively. See full prescribing information for SPINRAZA. SPINRAZA (nusinersen) injection, for intrathecal useInitial U.S. Approval: 2016
Spinraza®: coverage for all SMA type 1,2,3 patients - Institut de Myologie
Roche's low-price Evrysdi will take 'meaningful' SMA share from Biogen's Spinraza: analyst | FiercePharma
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
Official HCP Homepage | SPINRAZA® (nusinersen) | HCP
Spinraza™ represents the first FDA-approved drug for the treatment for... | Download Scientific Diagram
NHS to use world's most expensive drug to treat spinal muscular atrophy | NHS | The Guardian
Hydrocephalus a side effect of Spinraza? - SMA News Today Forums
NHS to use world's most expensive drug to treat spinal muscular atrophy | NHS | The Guardian
HSE approves Spinraza after lengthy campaign by patients
Safety | SPINRAZA® (nusinersen) HCP
